Family Care Hospitals
- Market cap
- ₹ 10 Cr.
- P/E
- 0.5x
- P/B
- 1.14x
- 52-week range
- 1.66 – 4.48
- ROE
- −38%
- ROCE
- −25.6%
- Dividend yield
- 0%
- Debt / equity
- 0.55
- Sector
- Healthcare Services
- Industry
- Healthcare Service Provider
- Listed on
- BSE
About
Family Care Hospitals Ltd is engaged in the business of healthcare services. The Company's hospitals serve the needs of their communities providing care for every individual. The Company serves its patients, employees, physicians, and partners. It offers general surgeries, such as hernias, gallstones, piles, and varicoceles. The Company also offers gynecology; orthopedics; ear, nose, and throat (ENT); cardiology; urology; oncology; plastic surgery, and proctology. Its gynecology services offer treatment for hysterectomy, ovarian cysts, fibroids, and pregnancy care. Its ENT services include sinusitis, tonsilitis, ear infection, and adenoids. Its urology services offer treatment for kidney stones, dialysis, urine infection, and prostate enlargement. Its oncology services offer treatment for breast cancer, oral cancer, gastrointestinal cancer, brain cancer, communities providing, and more. Its proctology services offer piles, anal fissures, anal fistula, perianal abscess, more.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Service Provider: 36 companies →Family Care Hospitals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)0.5 against a typical 21: cheaper than most peers (1st = cheapest).1st of 34
- Sales growth+150% against a typical +19.1% from a year earlier.2nd of 31
- Share price, 3 months−35.3% against a typical −7.7%.33rd of 33
- Size₹ 10.1 Cr. market value against a typical ₹ 83 Cr. (1st = largest).28th of 34
Financials
Standalone figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12 | 11 | 4 | 4 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 10 | 10 | 3 | 4 | −27 | 2 | 1 | 0 | 4 | 1 | −2 | 0 |
| Operating Profit | 2 | 1 | 1 | 0 | 31 | −2 | −1 | −0 | −4 | −1 | 2 | −0 |
| OPM % | 16.2% | 13.1% | 22.9% | 5.8% | 798.2% | −5,833.3% | −5,200% | −1,900% | −6,257.1% | −1,150% | 3,450% | −340% |
| Other Income | 0 | 1 | 2 | 0 | −74 | 0 | 2 | 0 | 0 | 0 | −4 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 2 | 3 | 0 | −43 | −2 | 1 | −1 | −5 | −1 | −2 | −0 |
| Tax % | 28.4% | 30.4% | −227.5% | 26.7% | −0.2% | 0% | −47.8% | 0% | 0% | 0% | 0% | 0% |
| Net Profit | 1 | 1 | 9 | 0 | −43 | −2 | 1 | −1 | −5 | −1 | −2 | −0 |
| EPS in Rs | 0.23 | 0.21 | 1.59 | 0.04 | −8.01 | −0.39 | 0.18 | −0.13 | −0.85 | −0.18 | −0.45 | −0.08 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- −15%
- 5 Years
- −64%
- 3 Years
- −83%
- TTM
- −94%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- −114%
- 10 Years
- −15%
- 5 Years
- −36%
- 3 Years
- −32%
- TTM
- —
- 10 Years
- 33%
- 5 Years
- 35%
- 3 Years
- 39%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Family Care Hospitals | ₹ 1.80 | ₹ 10 Cr. | 0.5x | 1.1x | −38% | — |
| Apollo Hospitals Enterprise | ₹ 7,731.95 | ₹ 1,11,174 Cr. | 64.9x | 13.4x | 22% | 7.8% |
| Max Healthcare Institute | ₹ 817.00 | ₹ 79,519 Cr. | 71.5x | 9.9x | 14.3% | 17.2% |
| Fortis Healthcare | ₹ 720.00 | ₹ 54,357 Cr. | 67.9x | 7.3x | 11.1% | 11.7% |
| Aster DM Healthcare | ₹ 651.00 | ₹ 56,817 Cr. | 102.6x | 9.3x | 9.7% | 9.2% |
| Narayana Hrudayalaya | ₹ 1,667.25 | ₹ 33,862 Cr. | 48.1x | 9.1x | 19.9% | 10.3% |
Management
- Rajesh Julal More
- Chief Financial Officer
- Sowmya Gautam Deshpande
- Chief Operating Officer
- Suchit Raghunath Modshing
- Executive Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.